RXi Pharmaceuticals announces plans to offer stock, warrants to public

By Angela McDaniels

Tacoma, Wash., April 13 – RXi Pharmaceuticals Corp. plans to price a public offering of common stock and warrants. H.C. Wainwright & Co., LLC is the agent.

Proceeds will be used for general corporate purposes, which include funding ongoing and future clinical trials and for general and administrative expenses, according to an S-1 filing with the Securities and Exchange Commission.

The company may also use a portion of the proceeds to acquire or invest in complementary businesses, products and technologies.

Marlborough, Mass.-based RXi is a biotechnology company with a focus on dermatology and ophthalmology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.